Medicine guide

Nuvaxovid

Prescription status not stated
Antibiotics, antivirals and antifungals taken into the body

Active substance: COVID-19 Vaccine (recombinant, adjuvanted)
Used in: Antibiotics, antivirals and antifungals taken into the body
Made by: Sanofi Winthrop Industrie
Source: Official label

Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.

What it is for

Nuvaxovid is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 12 years of age and older.The use of this vaccine should be in accordance with official recommendations. Nuvaxovid XBB.1.5 is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 12 years of age and older.The use of this vaccine should be in accordance with official recommendations. Nuvaxovid XFG is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 12 years of age and older. The use of this vaccine should be in accordance with official recommendations.

From the official label · 2026-09-30 · European Medicines Agency

Same active substance, strength and form in other countries

Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.

Medicine passport: one printable page to show a pharmacist abroad

SpainNo exact match for this strength and form

Every strength and form (10)

CanadaNo exact match for this strength and form

Every strength and form (2)

NetherlandsNo exact match for this strength and form

Every strength and form (6)

Details

Made by	Sanofi Winthrop Industrie
Active substance	COVID-19 Vaccine (recombinant, adjuvanted)
Used in	Antibiotics, antivirals and antifungals taken into the body
Classification	J07BN04 · Antibiotics, antivirals and antifungals taken into the body
Additional monitoring ▼	Yes — under additional monitoring (black triangle). Report suspected side effects.
Authorised on	2021-12-20
Last updated by the regulator	2026-08-10
EMA product number	EMEA/H/C/005808

Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician

Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).

Report wrong or outdated information on this page

Same active substance

These contain the same substance. That does not mean one can replace another — ask a pharmacist.

BimervaxEU authorisation Hipra Human Health S.L. · COVID-19 Vaccine (recombinant, adjuvanted) · J07BN VidPrevtyn BetaEU authorisation Sanofi Pasteur · COVID-19 Vaccine (recombinant, adjuvanted) · J07BN04

See every product with COVID-19 Vaccine (recombinant, adjuvanted)